KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Acquisitions: 2014-2025

  • Neogenomics' Acquisitions was N/A to $463,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $456.9 million, marking a year-over-year change of. This contributed to the annual value of $419.4 million for FY2021, which is 1033.52% up from last year.
  • Latest data reveals that Neogenomics reported Acquisitions of $463,000 as of Q3 2025, which was down 99.89% from $419.4 million recorded in Q2 2021.
  • In the past 5 years, Neogenomics' Acquisitions registered a high of $419.4 million during Q2 2021, and its lowest value of $463,000 during Q3 2025.
  • Over the past 1 years, Neogenomics' median Acquisitions value was $463,000 (recorded in 2025), while the average stood at $463,000.